Floatz logo

Therapeutic Asset Ratings

195 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
Ozanimod
Alzheimer Disease
ChenXiaoChunP2CCC (48)
PARTHENOLIDE (CONSTITUENT OF FEVERFEW)
Alzheimer Disease
Massachusetts General HospitalP2CCC (48)
PEGIPANERMIN
Alzheimer Disease
Inmune Bio, Inc.P2CCC (48)
Primec
Alzheimer Disease
NeuroSense Therapeutics Ltd.P2CCC (48)
Proleukin
Alzheimer Disease
Centre Hospitalier St AnneP2CCC (48)
Sci -110
Alzheimer Disease
The Israeli Medical Center for Alzheimer'sP2CCC (48)
Senicapoc
Alzheimer Disease
University of California, DavisP2CCC (48)
Siponimod
Alzheimer Disease
St. Joseph's Hospital and Medical Center, PhoenixP2CCC (48)
spg302
Alzheimer Disease
SpinogenixP2CCC (48)
Tadalafil
Alzheimer Disease
Imperial College LondonP2CCC (48)
Wei Li Bai Capsules
Alzheimer Disease
Capital Medical UniversityP2CCC (48)
Yangxue Qingnao Pills
Alzheimer Disease
Dongzhimen Hospital, BeijingP2CCC (48)
Ac-Ole-01-Va
Alzheimer Disease
CerecinP1CC (44)
BMS984923
Alzheimer Disease
Allyx TherapeuticsP1CC (44)
Npt 2042
Alzheimer Disease
NeuroPro Therapeutics, Inc.P1CC (44)
RO6958948
Alzheimer Disease
Washington University School of MedicineP1CC (44)
ABATACEPT RECOMBINANT
Alzheimer Disease
Massachusetts General HospitalP1/2CC (44)
Baricitinib
Alzheimer Disease
Massachusetts General HospitalP1/2CC (44)
Dasatinib
Alzheimer Disease
Mayo ClinicP1/2CC (44)
Midodrine
Alzheimer Disease
Applied CognitionP1/2CC (44)
PBR-06
Alzheimer Disease
Brigham and Women's HospitalP1/2CC (44)
Vedolizumab
Alzheimer Disease
Massachusetts General HospitalP1/2CC (42)
[18F]MC225
Alzheimer Disease
University Medical Center GroningenP1/2CC (41)
64Cu-FBP8
Alzheimer Disease
Massachusetts General HospitalP1/2CC (41)
Admsc
Alzheimer Disease
University Hospital, ToulouseP1/2CC (41)
Showing 101 to 125 of 195 assets
PreviousPage 5 of 8Next